Effects of a water-soluble forskolin derivative (NKH477) and a membrane-permeable cyclic AMP analogue on noradrenaline-induced Ca2+ mobilization in smooth muscle of rabbit mesenteric artery.
1. Effects were studied of 6-(3-dimethylaminopropionyl) forskolin (NKH477), a water-soluble forskolin derivative and of dibutyryl-cyclic AMP, a membrane-permeable cyclic AMP analogue on noradrenaline (NA)-induced Ca2+ mobilization in smooth muscle strips of the rabbit mesenteric artery. The intracellular concentration of Ca2+ ([Ca2+]i), isometric force and cellular concentration of inositol 1,4,5-trisphosphate (InsP3) were measured. 2. NA (10 microM) produced a phasic, followed by a tonic increase in both [Ca2+]i and force in a solution containing 2.6 mM Ca2+. NKH477 (0.01-0.3 microM) attenuated the phasic and the tonic increases in both [Ca2+]i and force induced by 10 microM NA, in a concentration-dependent manner. 3. In Ca(2+)-free solution containing 2 mM EGTA with 5.9 mM K+, NA (10 microM) produced only phasic increases in [Ca2+]i and force. NKH477 (0.01 microM) and dibutyryl-cyclic AMP (0.1 mM) each greatly inhibited these increases. 4. NA (10 microM) led to the production of InsP3 in intact smooth muscle strips and InsP3 (10 microM) increased Ca2+ in Ca(2+)-free solution after a brief application of Ca2+ in beta-escin-skinned smooth muscle strips. NKH477 (0.01 microM) or dibutyryl-cyclic AMP (0.1 mM) modified neither the NA-induced synthesis of InsP3 in intact muscle strips nor the InsP3-induced Ca2+ release in skinned strips. 5. In Ca(2+)-free solution, high K+ (40 and 128 mM) itself failed to increase [Ca2+]i but concentration-dependently enhanced the amplitude of the increase in [Ca2+]i induced by 10 microM NA with a parallel enhancement of the maximum rate of rise. The extent of the inhibition induced by NKH477 (0.01 microM)or dibutyryl-cyclic AMP (0.1 mM) on the NA-induced [Ca2+] increase was inversely related to the maximum rate of rise of [Ca2+], induced by NA in Ca2+-free solution containing various concentrations of K+. These results suggest that the increase in the rate of Ca2+ release induced by NA can conceal the inhibitory action on NA-induced Ca2+ mobilization of agents that increase cyclic AMP.6. Repetitive application of 10 JAM NA in Ca2+-free solution led to a disappearance of the NA-induced increase in [Ca2+]j, but NA could again increase [Ca2+], in Ca2+-free solution after a brief application of Ca2+ with 40 mM K+ ('Ca2+-loading'). The magnitude of this NA-induced increase in [Ca2+]i depended on the duration of the Ca2+-loading. With application of dibutyryl-cyclic AMP (0.1 mM) during the Ca2+-loading period, the loading duration required for the restoration of the maximum NA-response was shortened.7. Cyclopiazonic acid (10 microM, an inhibitor of Ca2+-ATPase at intracellular storage sites) attenuated the inhibitory action of dibutyryl-cyclic AMP on the NA-induced increase in [Ca2+], in Ca2+-free solution.When NA (10 microM) was applied twice for 30 s with a 10 min interval in Ca2+-free solution, the amplitude of response to the second application was about one third of the first response. With application of 0.1 mM dibutyryl-cyclic AMP during the first application of NA, the increase in [Ca2+], induced by the first application of NA was inhibited, but the response induced by the second was enhanced. These results suggest that dibutyryl-cyclic AMP enhances Ca2+ uptake into the NA-sensitive storage sites.8. We conclude that, in smooth muscle of the rabbit mesenteric artery, agents that increase cyclic AMP inhibit the NA-induced increase in [Ca2+] through an activation of Ca2+ uptake into the cellular storage sites.
Ito
S
S
Department of Pharmacology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Suzuki
S
S
Itoh
T
T
D000818:Animals; D003994:Bucladesine / Q000493:pharmacokinetics / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism*; D002463:Cell Membrane Permeability; D005576:Colforsin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D004928:Escin / Q000494:pharmacology; D015544:Inositol 1,4,5-Trisphosphate / Q000096:biosynthesis / Q000502:physiology; D008297:Male; D008638:Mesenteric Arteries / Q000187:drug effects / Q000378:metabolism; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000378:metabolism*; D009638:Norepinephrine / Q000494:pharmacology*; D011188:Potassium / Q000494:pharmacology; D011817:Rabbits; D012995:Solubility; D014665:Vasodilator Agents / Q000737:chemistry / Q000494:pharmacology*; D014867:Water
D014665:Vasodilator Agents; D014867:Water; D005576:Colforsin; D003994:Bucladesine; D004928:Escin; D015544:Inositol 1,4,5-Trisphosphate; D011188:Potassium; D002118:Calcium; D009638:Norepinephrine